Älvsjö, Sweden

Karin Nord


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Karin Nord: A Pioneer in Immunoglobulin G Research

Introduction

Karin Nord, an inventive mind based in Älvsjö, Sweden, has made significant contributions to the field of biotechnology. With a strong focus on immunology, she has developed innovations that enhance our understanding of immunoglobulin G (IgG) interactions.

Latest Patents

Karin Nord holds a patent for a groundbreaking invention titled "Polypeptide". This patent describes an immunoglobulin G Fc region binding polypeptide, which features a unique binding motif consisting of an amino acid sequence selected from specific variations. The invention not only identifies the binding motif, specifically EQQXAFYEILHLPNLTEXQXXAFIXXLRX (SEQ ID NO:12), but also includes methods for isolating or producing IgG Fc-containing molecules. This innovation stands to advance therapeutic applications in immune response modulation.

Career Highlights

Karin is currently associated with Affibody AB, a prominent player in the biotechnology sector. Her role at the company emphasizes her expertise in antibody technologies, particularly in enhancing the efficacy of therapeutic proteins. With one patent to her name, she is recognized for her impactful contributions to scientific research and development in immunology.

Collaborations

Throughout her career, Karin has collaborated with notable colleagues, including Anders Erik Jarstad and Thomas Bergman. These partnerships have fostered a collaborative environment that promotes innovative ideas and technological advancements in their field.

Conclusion

Karin Nord's work exemplifies the vital role that inventors play in advancing science and technology. Her innovative contributions in the area of immunoglobulin G research hold promise for future developments in therapeutic applications. As a leader at Affibody AB, Karin continues to pave the way for new discoveries that can significantly impact healthcare and biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…